Scarica l'app Stockscreener
19.96
0.71%
0.13
Dopo l'orario di chiusura:
19.96
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché AMPH Giù?
Forum
Previsione
Precedente Chiudi:
$19.83
Aprire:
$19.97
Volume 24 ore:
590.49K
Relative Volume:
1.48
Capitalizzazione di mercato:
$917.21M
Reddito:
$723.31M
Utile/perdita netta:
$111.63M
Rapporto P/E:
8.8503
EPS:
2.2553
Flusso di cassa netto:
$111.01M
1 W Prestazione:
-28.60%
1M Prestazione:
-30.20%
6M Prestazione:
-31.59%
1 anno Prestazione:
-27.70%
Intervallo 1D:
$19.56
$20.20
Intervallo di 1 settimana:
$19.56
$28.17
Portata 52W:
$19.56
$31.26
Amphastar Pharmaceuticals Inc Stock (AMPH) Company Profile
Nome
Amphastar Pharmaceuticals Inc
Settore
Telefono
909-980-9484
Indirizzo
11570 SIXTH STREET, RANCHO CUCAMONGA, CA
Compare AMPH vs TAK, ZTS, HLN, TEVA, UTHR
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AMPH
Amphastar Pharmaceuticals Inc
|
19.96 | 911.23M | 723.31M | 111.63M | 111.01M | 2.2553 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.22 | 57.12B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
125.98 | 53.16B | 9.47B | 2.67B | 2.28B | 6.0218 |
|
HLN
Haleon Plc Adr
|
10.48 | 47.25B | 14.54B | 2.22B | 2.58B | 0.4879 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.88 | 37.59B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
490.21 | 21.85B | 3.13B | 1.27B | 1.12B | 26.39 |
Amphastar Pharmaceuticals Inc Stock (AMPH) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-09 | Iniziato | Barclays | Equal Weight |
| 2025-08-12 | Aggiornamento | Needham | Hold → Buy |
| 2025-05-12 | Downgrade | JP Morgan | Overweight → Neutral |
| 2025-02-04 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2024-11-22 | Iniziato | Wells Fargo | Equal Weight |
| 2024-03-05 | Iniziato | JP Morgan | Overweight |
| 2023-11-17 | Iniziato | BofA Securities | Neutral |
| 2023-07-25 | Ripresa | Jefferies | Buy |
| 2022-10-21 | Ripresa | Jefferies | Buy |
| 2022-07-29 | Iniziato | CapitalOne | Overweight |
| 2022-01-07 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-01-08 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2020-10-05 | Aggiornamento | Northland Capital | Market Perform → Outperform |
| 2020-05-01 | Iniziato | Northland Capital | Outperform |
| 2019-03-13 | Downgrade | Needham | Buy → Hold |
| 2019-03-13 | Downgrade | Piper Jaffray | Overweight → Neutral |
| 2018-08-10 | Reiterato | Needham | Buy |
| 2018-03-13 | Reiterato | Needham | Buy |
| 2017-12-01 | Reiterato | Needham | Buy |
| 2017-11-09 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2017-09-27 | Reiterato | Needham | Buy |
| 2017-03-14 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2016-08-09 | Reiterato | Needham | Buy |
| 2016-05-10 | Reiterato | Needham | Buy |
| 2016-02-19 | Iniziato | Wells Fargo | Outperform |
| 2015-06-19 | Reiterato | Needham | Buy |
| 2015-06-03 | Iniziato | Raymond James | Strong Buy |
| 2014-07-21 | Iniziato | Needham | Buy |
Mostra tutto
Amphastar Pharmaceuticals Inc Borsa (AMPH) Ultime notizie
AMPH SEC FilingsAmphastar Pharma 10-K, 10-Q, 8-K Forms - Stock Titan
Royce & Associates LP Raises Stock Holdings in Amphastar Pharmaceuticals, Inc. $AMPH - MarketBeat
Amphastar Pharmaceuticals to Present at the Barclays 28th Annual Global Healthcare Conference - ACCESS Newswire
Amphastar Pharmaceuticals, Inc. (AMPH) Stock Analysis: Potential Upside of 38% Attracts Investor Attention - DirectorsTalk Interviews
Wells Fargo Sees Amphastar Pharmaceuticals, Inc.'s (AMPH) AMP-007 as Key to Mid- to High-Single-Digit Growth - Finviz
Wells Fargo Sees Amphastar Pharmaceuticals, Inc.’s (AMPH) AMP-007 as Key to Mid- to High-Single-Digit Growth - Yahoo Finance
Cash per share of Amphastar Pharmaceuticals, Inc. – DUS:29A - TradingView
Amphastar FDA Wins And Pipeline Expansion Contrast With Weak Earnings And Valuation - Yahoo Finance
Amphastar: Higher Costs, Lower Growth, And A 'Value Trap' Label (NASDAQ:AMPH) - Seeking Alpha
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Q4 2025 Earnings Call Transcript - Insider Monkey
Amphastar Pharmaceuticals Stock Hits New 12-Month Low After Analyst Downgrade - National Today
AMPH Stock (-24%): Q4 Earnings Miss Sparks Aggressive Liquidation - Trefis
Amphastar Pharmaceuticals Q4 2025 Report: Revenue Miss, Stock DeclineNews and Statistics - IndexBox
Amphastar Pharmaceuticals (NASDAQ:AMPH) Hits New 12-Month Low After Analyst Downgrade - MarketBeat
Amphastar stock hits 52-week low at $20.38 By Investing.com - Investing.com Australia
Amphastar Pharmaceuticals (NASDAQ:AMPH) Issues Quarterly Earnings Results - MarketBeat
Amphastar Pharmaceuticals Inc (29A.BE) Stock Price, News, Quote & History - Yahoo Finance
Amphastar stock hits 52-week low at $20.38 - Investing.com
Why Amphastar Pharmaceuticals (AMPH) Shares Are Plunging Today - Finviz
Wells Fargo & Company Has Lowered Expectations for Amphastar Pharmaceuticals (NASDAQ:AMPH) Stock Price - MarketBeat
Amphastar Pharmaceuticals (NASDAQ:AMPH) Shares Gap Down Following Analyst Downgrade - MarketBeat
Amphastar Pharmaceuticals (NASDAQ:AMPH) Price Target Lowered to $30.00 at Needham & Company LLC - MarketBeat
Amphastar Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Needham cuts Amphastar stock price target on Q4 miss, weak sales - Investing.com
TD Asset Management Inc Sells 103,038 Shares of Amphastar Pharmaceuticals, Inc. $AMPH - MarketBeat
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Amphastar Stock Pre-Market (-15%): Q4 Earnings and Revenue Miss - Trefis
Amphastar Pharmaceuticals (AMPH) Margin Compression Reinforces Bearish Narratives Despite Low 9.5x P/E - Sahm
Amphastar Pharmaceuticals Q4 Earnings Call Highlights - MarketBeat
Compared to Estimates, Amphastar (AMPH) Q4 Earnings: A Look at Key Metrics - Yahoo Finance
Amphastar Pharmaceuticals Inc reports results for the quarter ended September 30Earnings Summary - TradingView
Earnings call transcript: Amphastar’s Q4 2025 Misses Estimates, Stock Dips By Investing.com - Investing.com Canada
Amphastar (AMPH) Q4 2025 Earnings Call Transcript - AOL.com
Amphastar Pharmaceuticals (NASDAQ:AMPH) Misses Q4 CY2025 Revenue Estimates, Stock Drops 11.7% - Finviz
Amphastar Pharmaceuticals (AMPH) Q4 Earnings and Revenues Lag Estimates - Yahoo Finance
Amphastar Pharmaceuticals Inc. (AMPH) Stock Falls on Q4 2025 Earnings - Quiver Quantitative
Amphastar Pharmaceuticals Inc. (AMPH) stock falls on Q4 2025 Earnings - Quiver Quantitative
Amphastar Pharmaceuticals Reports Financial Results for Q4 and Full Year 2025 - TradingView
Earnings Flash (AMPH) Amphastar Pharmaceuticals, Inc. Reports Q4 Revenue $183.1M, vs. FactSet Est of $190.1M - marketscreener.com
Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full Year Ended December 31, 2025 - ACCESS Newswire
Amphastar Pharmaceuticals Q4 2025 Earnings: Release Date & Analyst OutlookNews and Statistics - IndexBox
Amphastar earnings on deck: Can pipeline offset flat growth? By Investing.com - Investing.com UK
Amphastar: Fourth Quarter Financial Overview - Bitget
Insights Ahead: Amphastar Pharma's Quarterly Earnings - Benzinga
Amphastar Pharmaceuticals (AMPH) Reports Earnings Tomorrow: What To Expect - Yahoo Finance UK
Amphastar Pharmaceuticals, Inc. (AMPH) Stock Analysis: Exploring a 14.60% Potential Upside - DirectorsTalk Interviews
Amphastar Announces FDA Approval for Ipratropium Bromide HFA - ACCESS Newswire
FDA clears Amphastar rival to Atrovent inhaler, 180-day exclusivity - Stock Titan
(AMPH) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Aug Reactions: Will Amphastar Pharmaceuticals Inc outperform the market in YEARWeekly Risk Report & Weekly Stock Breakout Alerts - baoquankhu1.vn
Amphastar Pharmaceuticals to Release Fourth Quarter Earnings and Hold Conference Call on February 26, 2026 - galvnews.com
Amphastar Pharmaceuticals Inc Azioni (AMPH) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Amphastar Pharmaceuticals Inc Azioni (AMPH) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Zhou Rong | SENIOR EVP, PRODUCTION CENTER |
Dec 17 '25 |
Sale |
26.20 |
9,787 |
256,379 |
138,043 |
| Petersen Floyd F. | Director |
Dec 12 '25 |
Sale |
25.92 |
2,426 |
62,888 |
71,368 |
| Petersen Floyd F. | Director |
Dec 11 '25 |
Sale |
25.69 |
1,737 |
44,620 |
73,794 |
0.49%
0.60%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):